Lobular carcinoma in situ: A 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk Journal Article
| Authors: | King, T. A.; Pilewskie, M.; Muhsen, S.; Patil, S.; Mautner, S. K.; Park, A.; Oskar, S.; Guerini Rocco, E.; Boafo, C.; Gooch, J. C.; De Brot, M.; Reis-Filho, J. S.; Morrogh, M.; Andrade, V. P.; Sakr, R. A.; Morrow, M. |
| Article Title: | Lobular carcinoma in situ: A 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk |
| Abstract: | Purpose The increased breast cancer risk conferred by a diagnosis of lobular carcinoma in situ (LCIS) is poorly understood. Here, we review our 29-year longitudinal experience with LCIS to evaluate factors associated with breast cancer risk. Patients and Methods Patients participating in surveillance after an LCIS diagnosis are observed in a prospectively maintained database. Comparisons were made among women choosing surveillance, with or without chemoprevention, and those undergoing bilateral prophylactic mastectomies between 1980 and 2009. Results One thousand sixty patients with LCIS without concurrent breast cancer were identified Median age at LCIS diagnosis was 50 years (range, 27 to 83 years). Fifty-six patients (5%) underwent bilateral prophylactic mastectomy; 1,004 chose surveillance with (n = 173) or without (n = 831) chemoprevention. At a median follow-up of 81 months (range, 6 to 368 months), 150 patients developed 168 breast cancers (63% ipsilateral, 25% contralateral, 12% bilateral), with no dominant histology (ductal carcinoma in situ, 35%; infiltrating ducta carcinoma, 29%; infiltrating lobular carcinoma, 27%; other, 9%). Breast cancer incidence was significantly reduced in women taking chemoprevention (10-year cumulative risk: 7% with chemoprevention; 21% with no chemoprevention; P <.001). In multivariable analysis, chemoprevention was the only clinical factor associated with breast cancer risk (hazard ratio, 0.27; 95% CI, 0.15 to 0.50). In a subgroup nested case-control analysis, volume of disease, which was defined as the ratio of slides with LCIS to total number of slides reviewed, was also associated with breast cancer development (P =.008) Conclusion We observed a 2% annual incidence of breast cancer among women with LCIS. Common clinical factors used for risk prediction, including age and family history, were not associated with breast cancer risk. The lower breast cancer incidence in women opting for chemoprevention highlights the potential for risk reduction in this population. © 2015 American Society of Clinical Oncology. All rights reserved. |
| Keywords: | adult; controlled study; human tissue; aged; cancer surgery; major clinical study; clinical feature; histopathology; cancer risk; cancer patient; follow up; cancer incidence; disease association; chemoprophylaxis; mastectomy; breast carcinoma; intraductal carcinoma; longitudinal study; lobular carcinoma in situ; bibliographic database; disease surveillance; human; female; priority journal; article |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 33 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-11-20 |
| Start Page: | 3945 |
| End Page: | 3952 |
| Language: | English |
| DOI: | 10.1200/JCO.2015.61.4743 |
| PROVIDER: | scopus |
| PUBMED: | 26371145 |
| PMCID: | PMC4934644 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 7 January 2016 -- 3945 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work